157 related articles for article (PubMed ID: 31417680)
1. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg
Roth K; Lehnick D; Wessels H; Höfler J; Gastl B; Jankowsky R
Pharmacol Res Perspect; 2019 Oct; 7(5):e00503. PubMed ID: 31417680
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics, safety, and immunogenicity of Pelmeg
Wessels H; Lehnick D; Höfler J; Jankowsky R; Chamberlain P; Roth K
Pharmacol Res Perspect; 2019 Oct; 7(5):e00507. PubMed ID: 31417681
[TBL] [Abstract][Full Text] [Related]
3. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects.
Singh I; Attrey A; Garg A; Patel R; Jose V
Clin Drug Investig; 2021 Jan; 41(1):29-42. PubMed ID: 33236287
[TBL] [Abstract][Full Text] [Related]
4. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects.
Nakov R; Gattu S; Wang J; Velinova M; Schaffar G; Skerjanec A
Br J Clin Pharmacol; 2018 Dec; 84(12):2790-2801. PubMed ID: 30079636
[TBL] [Abstract][Full Text] [Related]
5. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial.
Lickliter J; Kanceva R; Vincent E; Schueler A; Harrison-Moench E; Yue CS; Stahl M; Ullmann M; Ghori V; Griffin P
Clin Ther; 2020 Aug; 42(8):1508-1518.e1. PubMed ID: 32660769
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
Waller CF; Tiessen RG; Lawrence TE; Shaw A; Liu MS; Sharma R; Baczkowski M; Kothekar MA; Micales CE; Barve A; Ranganna GM; Pennella EJ
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1087-1095. PubMed ID: 29671069
[TBL] [Abstract][Full Text] [Related]
8. PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen
Yao HM; Ottery FD; Borema T; Harris S; Levy J; May TB; Moosavi S; Zhang J; Summers M
BioDrugs; 2019 Apr; 33(2):207-220. PubMed ID: 30900158
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects.
Singh I; Patel A; Patel R; Jose V
Cancer Chemother Pharmacol; 2018 Aug; 82(2):329-337. PubMed ID: 29948023
[TBL] [Abstract][Full Text] [Related]
10. Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim.
Desai K; Catalano T; Rai G; Misra P; Shah N
Clin Pharmacol Drug Dev; 2016 Sep; 5(5):354-63. PubMed ID: 27138868
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim.
Gattu S; Wang J; Bellon A; Schelcher C; Nakov R; Arani R
Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1130-1141. PubMed ID: 34350732
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2024 Mar; 41(3):991-1009. PubMed ID: 38180721
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence of a biosimilar enoxaparin sodium to Clexane
Martínez González J; Monreal M; Ayani Almagia I; Llaudó Garín J; Ochoa Díaz de Monasterioguren L; Gutierro Adúriz I
Drug Des Devel Ther; 2018; 12():575-582. PubMed ID: 29593380
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer.
Yao HM; Jones SR; Morales S; Moosavi S; Zhang J; Freyman A; Ottery FD
Cancer Chemother Pharmacol; 2021 Dec; 88(6):1033-1048. PubMed ID: 34618197
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta
Wynne C; Schwabe C; Vincent E; Schueler A; Ryding J; Ullmann M; Ghori V; Kanceva R; Stahl M
Pharmacol Res Perspect; 2020 Apr; 8(2):e00578. PubMed ID: 32333641
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
[TBL] [Abstract][Full Text] [Related]
18. Biosimilarity Assessment of 2 Filgrastim Therapeutics in Healthy Volunteers.
Khandoozi SR; Shahbazi M; Amini H
Clin Pharmacol Drug Dev; 2021 Apr; 10(4):346-352. PubMed ID: 32820861
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
[TBL] [Abstract][Full Text] [Related]
20. A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics.
Bellon A; Wang J; Skerjanec A; Velinova M; Dickerson D; Sabet A; Ngo L; O'Reilly T; Tomek C; Schussler S; Schier-Mumzhiu S; Gattu S; Koch SD; Schelcher C; Dobreva M; Boldea A; Nakov R; Otto GP
Br J Clin Pharmacol; 2020 Jun; 86(6):1139-1149. PubMed ID: 32022282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]